Free Newsletter
Nabi explores options after NicVAX flunks trial
Nabi Biopharmaceuticals ($NABI) was hit hard earlier this week after the company's smoking cessation vaccine NicVAX flunked a second late-stage trial. Data showed the primary endpoint was not met in the study, and there was no statistical difference between the NicVAX and placebo groups. The results echoed those of an earlier Phase III trial that were reported in July.
NicVAX was the subject of a $540 million deal with GlaxoSmithKline ($GSK) in 2009. The pharmaceutical giant pledged $40 million upfront for access to the company's vaccine and follow-ons that could result from its technology. A study of NicVAX in combination with Chantix (varenicline) remains ongoing in the Netherlands, and results are expected in the second half of 2012.
In announcing the disappointing study results, Nabi said it had brought on Piper Jaffray to explore strategic alternatives. "We are clearly disappointed with the results of this second NicVAX Phase III trial but not completely surprised," Nabi President and CEO Raafat Fahim said in a statement. "Our goal is to move expeditiously to maximize the value of the company's assets while continuing our effort to reduce our operating expenses."
- here's the Nabi release
Related Articles:
Nabi shares in meltdown after NicVAX flunks Ph3
Next-gen addiction vaccines offer a tough challenge to biotechs
Nabi scores $540 million pact with GSK for NicVAX
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: